Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia

著者: Étienne Crickx, Sylvain Audia, A. Robbins, David Boutboul, Thibault Comont, Morgane Cheminant, Éric Oksenhendler, Bertrand Godeau, Marc Michel, Matthieu Mahévas - Haematologica 2021 被引用: 50

Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia Immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (AIHA) are antibody-mediated autoimmune diseases in which plasma cells secrete pathogenic antibodies directed against platelet and red blood cell antigens. 1 Some patients show no response to first-or second-line treatments, including corticosteroids, rituximab, immunosuppressive drugs, splenectomy and, in the case of ITP, thrombopoietin receptor agonists, a situation that increases the risk of morbidity and mortality. In these refractory cases, persistent autoreactive long-lived plasma cells in the bone marrow could explain treatment failure.